Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Range Transverse-Momentum Correlations and Radial Flow in Pb-Pb Collisions at the LHC.

Physical review letters·2026
Same author

Enhanced Sensitivity of Sub-THz Thermomechanical Bolometers Exploiting Vibrational Nonlinearity.

ACS photonics·2026
Same author

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2025
Same author

First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.

Physical review letters·2025
Same author

Probing Strangeness Hadronization with Event-by-Event Production of Multistrange Hadrons.

Physical review letters·2025
Same author

Measurements of Chemical Potentials in Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2024
Same journal

Real-time algorithm-driven ventilation feedback to improve lung-protective ventilation in patients with ARDS (REALVENT-study): study protocol for a multicentre randomised controlled trial.

Respiratory research·2026
Same journal

Identification and functional validation of lactylation-related hub genes in idiopathic pulmonary fibrosis based on multi-omics analysis.

Respiratory research·2026
Same journal

NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.

Respiratory research·2026
Same journal

Direct visualisation and measurement of lung microstructure reveal insights into extracellular matrix dysregulation in COPD.

Respiratory research·2026
Same journal

Proteo-metabolomic insights into the progression of chronic obstructive pulmonary disease and lung function decline.

Respiratory research·2026
Same journal

Lung ultrasound feature tracking to quantify regional lung strain in mechanically ventilated pigs.

Respiratory research·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Where do we stand with IPF treatment?

C Albera1, C Ferrero, E Rindone

  • 1Università di Torino, Facoltà di Medicina e Chirurgia San Luigi Gonzaga, Dipartimento di Scienze Cliniche e Biologiche Scuola di Specializzazione in Malattie dell'Apparato Respiratorio, Torino, Italy. carlo.albera@unito.it

Respiratory Research
|June 6, 2013
PubMed
Summary
This summary is machine-generated.

Pirfenidone and N-acetylcysteine (NAC) are used for Idiopathic Pulmonary Fibrosis (IPF) despite weak guideline recommendations. Recent trials show mixed results, highlighting the need for updated IPF treatment guidelines.

Related Experiment Videos

Last Updated: May 10, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Idiopathic Pulmonary Fibrosis (IPF) treatment guidelines offer weak recommendations for pirfenidone and N-acetylcysteine (NAC).
  • Both pirfenidone and NAC are frequently used in clinical practice for IPF management.
  • Pirfenidone has demonstrated efficacy in Phase III trials and meta-analyses, with established tolerability data.

Purpose of the Study:

  • To review the current evidence for pirfenidone and NAC in IPF treatment.
  • To discuss the implications of recent clinical trial findings on IPF therapy.
  • To emphasize the need for updated clinical guidelines for IPF specialists.

Main Methods:

  • Review of Phase III clinical trials for pirfenidone and NAC in IPF.
  • Analysis of a Cochrane meta-analysis on pirfenidone efficacy.
  • Examination of recent trial data, including a study stopped due to increased mortality.

Main Results:

  • Pirfenidone efficacy is supported by robust clinical trial data and meta-analyses.
  • NAC-based therapy lacks formal approval but is common; a trial suggested limited benefit.
  • A recent triple-therapy trial (NAC, prednisone, azathioprine) was halted due to higher mortality.

Conclusions:

  • Existing guidelines for IPF treatment require updating based on current evidence.
  • IPF specialists need updated guidance to provide optimal patient care.
  • Further research and guideline revisions are crucial for managing IPF effectively.